CBAY Stock Overview
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$3.28|
|52 Week High||US$7.44|
|52 Week Low||US$3.18|
|1 Month Change||-28.70%|
|3 Month Change||-16.75%|
|1 Year Change||-54.44%|
|3 Year Change||-61.86%|
|5 Year Change||81.22%|
|Change since IPO||-63.56%|
Recent News & Updates
Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
We Think CymaBay Therapeutics (NASDAQ:CBAY) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...
|CBAY||US Pharmaceuticals||US Market|
Return vs Industry: CBAY underperformed the US Pharmaceuticals industry which returned 12.4% over the past year.
Return vs Market: CBAY underperformed the US Market which returned 19.4% over the past year.
|CBAY Average Weekly Movement||7.1%|
|Pharmaceuticals Industry Average Movement||9.4%|
|Market Average Movement||6.1%|
|10% most volatile stocks in US Market||14.8%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: CBAY is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: CBAY's weekly volatility (7%) has been stable over the past year.
About the Company
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics; and CB-0406, which is in Phase I clinical trial for the inflammation disease/condition.
CymaBay Therapeutics Fundamentals Summary
|CBAY fundamental statistics|
Is CBAY overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CBAY income statement (TTM)|
|Cost of Revenue||US$38.37m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.94|
|Net Profit Margin||0.00%|
How did CBAY perform over the long term?See historical performance and comparison
Is CymaBay Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate CBAY's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate CBAY's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: CBAY is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: CBAY is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CBAY's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CBAY is overvalued based on its PB Ratio (3.2x) compared to the US Pharmaceuticals industry average (2.7x).
How is CymaBay Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CBAY is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CBAY is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CBAY is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CBAY's revenue (85.8% per year) is forecast to grow faster than the US market (10% per year).
High Growth Revenue: CBAY's revenue (85.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CBAY's Return on Equity is forecast to be high in 3 years time
How has CymaBay Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CBAY is currently unprofitable.
Growing Profit Margin: CBAY is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CBAY is unprofitable, and losses have increased over the past 5 years at a rate of 19.9% per year.
Accelerating Growth: Unable to compare CBAY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CBAY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).
Return on Equity
High ROE: CBAY has a negative Return on Equity (-90.98%), as it is currently unprofitable.
How is CymaBay Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: CBAY's short term assets ($119.6M) exceed its short term liabilities ($11.7M).
Long Term Liabilities: CBAY's short term assets ($119.6M) exceed its long term liabilities ($24.1M).
Debt to Equity History and Analysis
Debt Level: CBAY has more cash than its total debt.
Reducing Debt: CBAY's debt to equity ratio has reduced from 92.8% to 26.7% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CBAY has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CBAY has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 22.9% each year.
What is CymaBay Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CBAY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CBAY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CBAY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CBAY's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CBAY's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sujal Shah (48 yo)
Mr. Sujal A. Shah serves as Director at Tvardi Therapeutics, Inc. since January 2021. He has been the Chief Executive Officer and President of Cymabay Therapeutics, Inc, since November 6, 2017. Mr. Shah se...
CEO Compensation Analysis
Compensation vs Market: Sujal's total compensation ($USD2.64M) is above average for companies of similar size in the US market ($USD1.15M).
Compensation vs Earnings: Sujal's compensation has increased whilst the company is unprofitable.
Experienced Management: CBAY's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Experienced Board: CBAY's board of directors are considered experienced (5.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 22.9%.
CymaBay Therapeutics, Inc.'s employee growth, exchange listings and data sources
- Name: CymaBay Therapeutics, Inc.
- Ticker: CBAY
- Exchange: NasdaqGS
- Founded: 1988
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$277.714m
- Shares outstanding: 84.67m
- Website: https://www.cymabay.com
Number of Employees
- CymaBay Therapeutics, Inc.
- 7575 Gateway Boulevard
- Suite 110
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/03 23:52|
|End of Day Share Price||2021/12/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.